rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2007-47-54rsp-2187Research ArticleОБЗОРREVIEWМЕСТО ПЛАЗМАФЕРЕЗА В ЛЕЧЕНИИ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙPlace of plasmapheresis in the treatment of rheumatic diseasesСоловьевС. К.SolovjovS. K.
Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-80
АсееваЕ. А.AseevaE. A.
Адрес: 115522 Москва, Каширское шоссе, 34а, Тел/факс: 8-499-614-44-80
ГУ Институт ревматологии РАМН, МоскваРоссия2007120520164544754Copyright © Соловьев С.К., Асеева Е.А., 20162016Соловьев С.К., Асеева Е.А.Solovjov S.K., Aseeva E.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2187
.
.
ReferencesCampion E. Desperate diseases and plasmapheresis. N.Engl.J.Med.,1992, 326,1425–1427Campion E. Desperate diseases and plasmapheresis. N.Engl.J.Med.,1992, 326,1425–1427Von Baeyer H. Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience.Ther. Apher. Dial., 2003, 7(1),127-40Von Baeyer H. Plasmapheresis in immune hematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience.Ther. Apher. Dial., 2003, 7(1),127-40Lewis EJ. Plasmapheresis in collagen vascular diseases. Ther. Apher., 1999 3(2), 172-177Lewis EJ. Plasmapheresis in collagen vascular diseases. Ther. Apher., 1999 3(2), 172-177Pagnoux C., Korach J.-M. , Guillevin. L. Indications for plasma exchange in systemic lupus erythematosus in 2005. Lupus, 2005, 14, 871-877.Pagnoux C., Korach J.-M. , Guillevin. L. Indications for plasma exchange in systemic lupus erythematosus in 2005. Lupus, 2005, 14, 871-877.Jones J.V., Robinson M.F., Parciany R.K. et al. Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA. Arthr. Rheum., 1981, 24, 1113–1120Jones J.V., Robinson M.F., Parciany R.K. et al. Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA. Arthr. Rheum., 1981, 24, 1113–1120Rifle G., Mousson C., Tanter Y. Hemapheresis in systemic lupus erythematosus. Clin. Exp. Rheumatol., 1990, 8(suppl. 5), 51–55Rifle G., Mousson C., Tanter Y. Hemapheresis in systemic lupus erythematosus. Clin. Exp. Rheumatol., 1990, 8(suppl. 5), 51–55Soltesz P., Aleksza M., Antal-Szalmas P. et al. Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmun., 2002, 35(1),51–56Soltesz P., Aleksza M., Antal-Szalmas P. et al. Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines. Autoimmun., 2002, 35(1),51–56Jones J.V.,Cumming R.H.,Bacon P.A. et al. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.QJ Med., 1979, 48,555–576.Jones J.V.,Cumming R.H.,Bacon P.A. et al. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.QJ Med., 1979, 48,555–576.Bonomini V., Vangelista A., Frasca G.M. et al. Effect of plasmapheresis on cellular immunity abnormalitiesin patients with systemic lupus erythematosus. Clin. Nephrol., 1984, 22,121–126Bonomini V., Vangelista A., Frasca G.M. et al. Effect of plasmapheresis on cellular immunity abnormalitiesin patients with systemic lupus erythematosus. Clin. Nephrol., 1984, 22,121–126Lewis E.J.. Plasmapheresis for the treatment of severe lupus nephritis:uncontrolled observations. Am. J. Kidney Dis., 1982, 2,182–187Lewis E.J.. Plasmapheresis for the treatment of severe lupus nephritis:uncontrolled observations. Am. J. Kidney Dis., 1982, 2,182–187Wallace D.J. Apheresis for lupus erythematosus. Lupus; 1999;8(3),174-80Wallace D.J. Apheresis for lupus erythematosus. Lupus; 1999;8(3),174-80Lewis E.J., Hunsicker L.G., Lan S.P. et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N. Engl. J. Med., 1992, 326,1373–1379Lewis E.J., Hunsicker L.G., Lan S.P. et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N. Engl. J. Med., 1992, 326,1373–1379Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis. Ther. Apher., 2001, 5(3),161-170.Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis. Ther. Apher., 2001, 5(3),161-170.Nakamura T., Ushiyama C., Hara M. et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis. Clin. Nephrol., 2002, 57(2),108-113Nakamura T., Ushiyama C., Hara M. et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative Lupus nephritis. Clin. Nephrol., 2002, 57(2),108-113Schroeder J.O., Euler H.H., Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann. Intern. Med., 1987, 107, 344–346.Schroeder J.O., Euler H.H., Loffler H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann. Intern. Med., 1987, 107, 344–346.Euler H.H., Schroeder J.O. Antibody depletion and cytotoxic drug therapy in severe systemic lupus erythematosus. Transfus. Sci., 1992, 13, 167–184Euler H.H., Schroeder J.O. Antibody depletion and cytotoxic drug therapy in severe systemic lupus erythematosus. Transfus. Sci., 1992, 13, 167–184Danieli M.G., Palmieri C., Salvi A. et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J. Clin. Apher., 2002,17(2),72-77.Danieli M.G., Palmieri C., Salvi A. et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J. Clin. Apher., 2002,17(2),72-77.Euler H.H., Schroeder J.O., Harten P. et al. Treatmentfree remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthr. Rheum., 1994, 37(12),1784-1794.Euler H.H., Schroeder J.O., Harten P. et al. Treatmentfree remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthr. Rheum., 1994, 37(12),1784-1794.Dau P.C., Callahan J., Parker R., Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J. Rheumatol., 1991,18(2),270-276Dau P.C., Callahan J., Parker R., Golbus J. Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J. Rheumatol., 1991,18(2),270-276Hanly J.G., Hong C., Zayed E. et al. Immunomodulating effects of synchronized plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus, 1995,4(6),457-463Hanly J.G., Hong C., Zayed E. et al. Immunomodulating effects of synchronized plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus, 1995,4(6),457-463Wallace D.J., Goldfinger D., Pepkowitz S.H. et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J. Clin. Apher., 1998, 13,163–166Wallace D.J., Goldfinger D., Pepkowitz S.H. et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J. Clin. Apher., 1998, 13,163–166Danieli M.G., Palmieri C., Salvi A. et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J. Clin. Apher., 2002, 17,72–77Danieli M.G., Palmieri C., Salvi A. et al. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J. Clin. Apher., 2002, 17,72–77Saracyn M., Korsak J., Wankowicz Z. Plasmapheresis in a case of necessary discontinuation of cyclophosphamide in the treatment of severe lupus nephritis. Pol. Merkuriusz Lek., 2004,17(98),162-164.Saracyn M., Korsak J., Wankowicz Z. Plasmapheresis in a case of necessary discontinuation of cyclophosphamide in the treatment of severe lupus nephritis. Pol. Merkuriusz Lek., 2004,17(98),162-164.Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis. Ther. Apher., 2001 Jun,5(3),161-170Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis. Ther. Apher., 2001 Jun,5(3),161-170Hristea D., Hadaya K., Marangon N. et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl. Int., 2007, 20(1),102-105Hristea D., Hadaya K., Marangon N. et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl. Int., 2007, 20(1),102-105Stegmayr B., Korach J.M., Norda R. et al. Is there a need for a national or a global apheresis registry? Trans. Apher., Sci., 2003, 29, 179–185.Stegmayr B., Korach J.M., Norda R. et al. Is there a need for a national or a global apheresis registry? Trans. Apher., Sci., 2003, 29, 179–185.Norda R., Stegmayr B.G. Apheresis registry in Sweden, scope, techniques and indications for treatment. A report from the Swedish Apheresis Study Group. Trans. Apher. Sci., 2001, 24, 49–55Norda R., Stegmayr B.G. Apheresis registry in Sweden, scope, techniques and indications for treatment. A report from the Swedish Apheresis Study Group. Trans. Apher. Sci., 2001, 24, 49–55Raj R., Murin S,. Matthay R.A., Wiedemann H.P. Systemic lupus erythematosus in the intensive careunit. Crit. Care Clin., 2002, 18, 781–803.Raj R., Murin S,. Matthay R.A., Wiedemann H.P. Systemic lupus erythematosus in the intensive careunit. Crit. Care Clin., 2002, 18, 781–803.Wallace D.J. Apheresis for lupus erythematosus: state of the art. Lupus, 2001, 10, 193–196Wallace D.J. Apheresis for lupus erythematosus: state of the art. Lupus, 2001, 10, 193–196Braun-Moscovici Y., Furst. D.E. Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it? Curr. Opin. Rheumatol., 2003, 15,197–204Braun-Moscovici Y., Furst. D.E. Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it? Curr. Opin. Rheumatol., 2003, 15,197–204Hoshi K., Matsuda M., Ishikawa M. et al. Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin . Rheumatol., 2004,23(3),252-255.Hoshi K., Matsuda M., Ishikawa M. et al. Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin . Rheumatol., 2004,23(3),252-255.Badsha H., Teh C.L., Kong K.O. et al. Pulmonary hemorrhage in systemic lupus erythematosus. Semin. Arthr. Rheum., 2004, 33(6),414-421Badsha H., Teh C.L., Kong K.O. et al. Pulmonary hemorrhage in systemic lupus erythematosus. Semin. Arthr. Rheum., 2004, 33(6),414-421Jennekens F.G.I., Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatol., 2002, 41,605-618Jennekens F.G.I., Kater L. The central nervous system in systemic lupus erythematosus. Part 1. Clinical syndromes: a literature investigation. Rheumatol., 2002, 41,605-618Vadacca M., Buzzulini F., Rigon A. et al., Neuropsychiatric lupus erythematosus. Reumatismo, 2006,58(3),177-186)Vadacca M., Buzzulini F., Rigon A. et al., Neuropsychiatric lupus erythematosus. Reumatismo, 2006,58(3),177-186)Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther. Apher. Dial., 2003, 7(2),173-182.Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther. Apher. Dial., 2003, 7(2),173-182.Hanly J.G., Harrison M.J. Management of neuropsychiatric lupus. Best Pract. Res. Clin. Rheumatol., 2005,19(5),799-821Hanly J.G., Harrison M.J. Management of neuropsychiatric lupus. Best Pract. Res. Clin. Rheumatol., 2005,19(5),799-821Espinosa G., Bucciarelli S., Cervera R. et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann.Rheum. Dis., 2004, 63, 730–736.Espinosa G., Bucciarelli S., Cervera R. et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann.Rheum. Dis., 2004, 63, 730–736.Bray V.J.,West S.G., Kristo D.A. Simultaneous presentation of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med. J., 1994, 87, 827–830.Bray V.J.,West S.G., Kristo D.A. Simultaneous presentation of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med. J., 1994, 87, 827–830.Levine S., Shearn M.A. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Arch. Intern. Med., 1964, 113,826– 836.Levine S., Shearn M.A. Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Arch. Intern. Med., 1964, 113,826– 836.Brunner H.I., Freedman M., Silverman E.D. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthr. Rheum 1999, 42, 2346–2355.Brunner H.I., Freedman M., Silverman E.D. Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthr. Rheum 1999, 42, 2346–2355.Guvenc B., Unsal C., Gurkan E. et.al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report. Transfus. Apher. Sci., 2004,31(1),17-20.Guvenc B., Unsal C., Gurkan E. et.al. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura: a case report. Transfus. Apher. Sci., 2004,31(1),17-20.Aleem A., Al-Sugair S. Thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Acta Haematol., 2006,115 (1- 2), 68-73.Aleem A., Al-Sugair S. Thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus. Acta Haematol., 2006,115 (1- 2), 68-73.Masseau A., Guitton C., Bretonniere C . et al. Plasma exchanges as treatment of severe acute immune thrombocytopenic purpura. Rev. Med . Interne, 2005,26(10),824-826.Masseau A., Guitton C., Bretonniere C . et al. Plasma exchanges as treatment of severe acute immune thrombocytopenic purpura. Rev. Med . Interne, 2005,26(10),824-826.Song H.J., Suh Y.J., Suh C.H. Synchronization of plasma-pheresis and pulse cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura and SLE associated with pregnancy. Clin. Exp .Rheumatol., 2003,21(4),523.Song H.J., Suh Y.J., Suh C.H. Synchronization of plasma-pheresis and pulse cyclophosphamide in the treatment of thrombotic thrombocytopenic purpura and SLE associated with pregnancy. Clin. Exp .Rheumatol., 2003,21(4),523.Stricker R.B., Davis J.A., Gershow J. et al. Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era. J. Rheumatol.,1992, 19,1469–1473Stricker R.B., Davis J.A., Gershow J. et al. Thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus. Case report and literature review from the plasmapheresis era. J. Rheumatol.,1992, 19,1469–1473Asherson R.A., Espinosa G., Cervera R. et al., Catastrophic Antiphospholipid Syndrome: Proposed Guidelines for Diagnosis and Treatment. J. Clin . Rheumatol., 2002, 8(3),157-165Asherson R.A., Espinosa G., Cervera R. et al., Catastrophic Antiphospholipid Syndrome: Proposed Guidelines for Diagnosis and Treatment. J. Clin . Rheumatol., 2002, 8(3),157-165Castro P., Venegas R., Fardella P. et al. Catastrophic antiphospholipid syndrome and acute heart failure. Report of a case. Rev. Med. Chil., 2003,131(9),1037- 1041.Castro P., Venegas R., Fardella P. et al. Catastrophic antiphospholipid syndrome and acute heart failure. Report of a case. Rev. Med. Chil., 2003,131(9),1037- 1041.Cervera R., Asherson R.A., Font J. Catastrophic antiphospholipid syndrome. Rheum. Dis. Clin. North Am., 2006,32(3),575-590Cervera R., Asherson R.A., Font J. Catastrophic antiphospholipid syndrome. Rheum. Dis. Clin. North Am., 2006,32(3),575-590Ahn E.R., Lander G., Bidot C.J. et al., Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am. J. Hematol., 2005,78(2),127-129Ahn E.R., Lander G., Bidot C.J. et al., Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am. J. Hematol., 2005,78(2),127-129Van Eer M.Y,. Netten P.M., Schrijver G. et al. Sjogren’ssyndrome complicated by cryoglobulinemia and acute renal failure. Neth. J. Med., 1991, 39,23– 27.Van Eer M.Y,. Netten P.M., Schrijver G. et al. Sjogren’ssyndrome complicated by cryoglobulinemia and acute renal failure. Neth. J. Med., 1991, 39,23– 27.Васильев В.И., Соловьев С.К., Чикликчи А.С. и соавт. Положительный эффект комбинированной терапии (плазмаферез в комбинации с пульс-терапией) на течение криоглобулинемического нефрита и язвенно-некротического васкулита при болезни Шегрена. Тер.aрхив., 1987,59,54-59Васильев В.И., Соловьев С.К., Чикликчи А.С. и соавт. Положительный эффект комбинированной терапии (плазмаферез в комбинации с пульс-терапией) на течение криоглобулинемического нефрита и язвенно-некротического васкулита при болезни Шегрена. Тер.aрхив., 1987,59,54-59Guillevin L.,Fain O.,Lhote F. et al. Lack of superiority of steroids plus plasma Exchange to steroids alone in the treatment of polyarteritis nodosa and Churg- Strauss syndrome. A prospective randomized trial in 78 patients. Arthr. Rheum., 1992, 35,208–215.Guillevin L.,Fain O.,Lhote F. et al. Lack of superiority of steroids plus plasma Exchange to steroids alone in the treatment of polyarteritis nodosa and Churg- Strauss syndrome. A prospective randomized trial in 78 patients. Arthr. Rheum., 1992, 35,208–215.Guillevin L.,LhoteF., Cohen P. et al. Lack of superiority of corticosteroids plus pulse cyclophosphamide and plasma exchanges to corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg- Strauss syndrome patients with poor prognostic factors. A prospective randomized trial in sixty-two patients. Arthr. Rheum., 1995, 38,1638–1645.Guillevin L.,LhoteF., Cohen P. et al. Lack of superiority of corticosteroids plus pulse cyclophosphamide and plasma exchanges to corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg- Strauss syndrome patients with poor prognostic factors. A prospective randomized trial in sixty-two patients. Arthr. Rheum., 1995, 38,1638–1645.Stegmayr B.G., Almroth G., Berlin G. et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int. J. Artif. Organs, 1999, 22,81–87Stegmayr B.G., Almroth G., Berlin G. et al. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int. J. Artif. Organs, 1999, 22,81–87Gaskin G., Pusey C.D. Plasmapheresis in antineutrophil cytoplasmic antibodies-associated systemic vasculitis. Ther. Apher. 2001, 5,176–181Gaskin G., Pusey C.D. Plasmapheresis in antineutrophil cytoplasmic antibodies-associated systemic vasculitis. Ther. Apher. 2001, 5,176–181Caldwell J., Gendreau R.M., Furst D. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid Arthr. J. Rheumatol., 1999, 26(8),1657–1662Caldwell J., Gendreau R.M., Furst D. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid Arthr. J. Rheumatol., 1999, 26(8),1657–1662Felson D.T., LaValley M.P., Baldassare A.R. et al.. The Prosorba column for treatment of refractory rheumatoid Arthritis: a randomized, doubleblind, shamcontrolled trial. Arthr. Rheum., 1999, 42(10),2153–2159Felson D.T., LaValley M.P., Baldassare A.R. et al.. The Prosorba column for treatment of refractory rheumatoid Arthritis: a randomized, doubleblind, shamcontrolled trial. Arthr. Rheum., 1999, 42(10),2153–2159Gendreau R.M. A randomized double-blind shamcontrolled trial of the Prosorba column for treatment of refractory rheumatoid arthritis.. Ther. Apher., 2001, 5(2),80–83Gendreau R.M. A randomized double-blind shamcontrolled trial of the Prosorba column for treatment of refractory rheumatoid arthritis.. Ther. Apher., 2001, 5(2),80–83Miller F.W., Leitman S.F., Cronin M.E. et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N. Engl. J . Med., 1992, 326,1380–1386Miller F.W., Leitman S.F., Cronin M.E. et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N. Engl. J . Med., 1992, 326,1380–1386Mori M., Tomono N., Yokota S. Coronary arteritis of Kawasaki Disease unresponsive to high dose intravenous gammaglobulin successfully treated with plasmapheresis. Nikon Rinsho Meneki Gakkai Kaishi, 1995, 18,282–288Mori M., Tomono N., Yokota S. Coronary arteritis of Kawasaki Disease unresponsive to high dose intravenous gammaglobulin successfully treated with plasmapheresis. Nikon Rinsho Meneki Gakkai Kaishi, 1995, 18,282–288Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis.Ther. Apher., 2001, 5,161–170Mistry-Burchardi N., Schonermarck U., Samtleben W. Apheresis in lupus nephritis.Ther. Apher., 2001, 5,161–170Aringer M., Smolen J.S., Graninger W.B. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthr. Rheum., 1998, 41, 414–420Aringer M., Smolen J.S., Graninger W.B. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthr. Rheum., 1998, 41, 414–420Pohl M.A., Lan S.P., Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann. Intern. Med., 1991, 114, 924–929Pohl M.A., Lan S.P., Berl T. Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann. Intern. Med., 1991, 114, 924–929Асеева Е.А.., Соловьев С.К.,Чикликчи А.С., Насонова В.А. Синхронная программная интенсивная терапия у больных с тяжелым течением ревматоидного артрита. Тер. архив, 2002. 5, 112-118.Асеева Е.А.., Соловьев С.К.,Чикликчи А.С., Насонова В.А. Синхронная программная интенсивная терапия у больных с тяжелым течением ревматоидного артрита. Тер. архив, 2002. 5, 112-118.
The authors declare that there are no conflicts of interest present.